Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the post-slider-and-carousel domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home1/qordata/stg.qordata.com/wp-includes/functions.php on line 6114
Disclosure, EFPIA, Pharma Compliance – qordata is a Data-Driven Compliance Platform Provider

Category: Disclosure, EFPIA, Pharma Compliance

Explore our library of blogs, insights, research papers, and more information on compliance in the life sciences industry.

On November 16, 2020, the Office of the Inspector General issued a Special Fraud Alert. This was the first Special Fraud Alert in six years and the fourth one issued in the past two decades. Given that the Fraud Alert was released after years of observing the way the pharmaceutical companies and device manufacturers were […]

Compliance challenges, evolving rules and regulations, building a data-driven compliance program, and false claims that lead to indictment and penalties continue to be trending topics in the world of compliance. The Department of Justice (DOJ) recovered over $3 Billion from the False Claims Act case in the fiscal year 2019. Of the more than $3 […]

Data-driven compliance solutions have proven their viability and effectiveness in the world of life science compliance over the years by enabling compliance professionals to mitigate critical risks and significantly reduce pressure. Whether it is identifying red flags associated with engaging HCPs, pinpointing errors in an aggregate spend report prior to CMS submission, or monitoring compliance […]

The design of a compliance program determines its effectiveness in preventing and detecting compliance risks, i.e., misconduct, breach of internal policies, or the policies imposed by the government. It is responsible for determining if the corporate management is enforcing the program or is tacitly encouraging employees to engage in misconduct. This is one of the […]

The U.S Department of Justice (DOJ) updated its compliance program evaluation guideline outlining exactly how it evaluates corporate compliance programs. The new guidance instructed prosecutors to ask life sciences companies’ compliance teams whether they have data sources for timely, effective, and efficient monitoring and whether they are continuously testing and updating policies, controls, and transactions. […]

The answer to “is managing compliance really that difficult?” is that it is and isn’t at the same time. To understand this, we must look beyond conventional compliance practices, evaluate factors influencing compliance positively or negatively, and determine what makes compliance difficult and how companies can reduce the pressure. So, let’s explore both sides to […]